|
Guidance Outlines Effectiveness Summary for NDAs and BLAs
The integrated summary of effectiveness (ISE) required in new drug applications (NDAs) and encouraged in biologic licensing applications (BLAs) should include a detailed analysis of study results rather than just a summary of individual trials, according to a U.S. Food and Drug Administration (FDA) draft guidance.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
|
Subscribe
Archives